This snapshot, taken on
02/11/2012
, shows web content acquired for preservation by The National Archives. External links, forms and search may not work in archived websites and contact details are likely to be out of date.
 
 
The UK Government Web Archive does not use cookies but some may be left in your browser from archived websites.

CDR Weekly
  Search CDR




Adobe AcrobatCurrent Issue in PDF format

This site uses Adobe Acrobat

Download here >

 

Final Issue: Volume 16 Number 51

Published on: 21 December 2006

Final Issue in PDF Current Issue in PDF format
PDF format (283 Kb)

News Archives

Last updated: Volume 15, No.23 (PDF file, 221 KB)

Archives | News Archives 2006: Page 1| 9 June 2005

News Archives: | 2006 | 2005 | 2004 | 2003

Changes to the mandatory surveillance system for MRSA: new CMO/CNO letter

 

The Chief Medical Officer (CMO) and Chief Nursing Officer (CNO) for England published a new letter about changes to mandatory surveillance of methicillin resistant Staphylococcus aureus (MRSA) bacteraemias (1).The letter, aimed at a wide range of healthcare professionals, is based on a previous communication from June 2003 (2) and the changes are intended to provide a better evidence base for national policy.

Mandatory surveillance of MRSA bacteraemias by acute NHS hospital Trusts began in April 2001 and the Department of Health has now published over three years’ data. The Secretary of State for Health announced in March 2005 that these data will now be published six-monthly rather than annually. The first six-monthly dataset was published on 7 March 2005, together with the previous three years’ data arranged in a six-monthly format. These tables can be consulted on the DH website (3).

There are two main changes to the mandatory surveillance of MRSA bacteraemia being announced:

(i) Monthly reporting of MRSA bacteraemias from 1 April 2005 to monitor Trusts’ trajectory towards meeting their target (4). The reports for MRSA data covering April and May must be submitted by 15 June and for all months onwards by the 15th of the following month. The existing quarterly reports should continue.

(ii) Enhancements to the MRSA dataset. The Department of Health has asked the Health Protection Agency (HPA) to develop a new enhanced reporting system for MRSA bacteraemia surveillance, which will allow the capture of more comprehensive data on MRSA, including information on where the infection was acquired. It is expected that this enhanced system will be helpful in giving Trusts a more accurate picture of their performance and in developing a better evidence base for prevention of infections. Twenty-one Trusts are already using this system on a trial basis in preparation for extending the scheme to all acute Trusts by October 2005. The enhancements to the mandatory dataset result from the findings of the MRSA Bacteraemia Surveillance User Survey, which all Trusts participated in recently. This indicated that many Trusts were already collecting additional information on MRSA bacteraemias, such as where the infection was acquired. The final report of the User Survey is expected shortly.

The letter also details that this data must be reported under the mandatory surveillance system so that there are no variations in reporting between Trusts. It is clear that Chief Executives are expected to ensure that reporting from their Trusts meet the criteria.

The enhancements that are being introduced over the next few months will generate a more detailed and informative evidence base on the incidence of Staphylococcus aureus bacteramias.

References

 

1.Department of Health (Chief Medical Officer/Chief Nursing Officer).CMO/CNO Letter PL/CMO/2005/4, PL/CNO/2005/4. Mandatory surveillance of methicillin resistant Staphylococcus Aureus (MRSA) bacteraemias. London: Department of Health, 9 June 2005. Available at: <http://www.dh.gov.uk/assetRoot/04/11/25/90/04112590.pdf>.

2.Department of Health (Chief Medical Officer). CMO Letter PL/CMO/2003/4, PL/CNO/2003/4, Surveillance of Healthcare Associated Infections. London: Department of Health, 9 June 2003. Available at:
<http://www.dh.gov.uk/assetRoot/04/01/34/10/04013410.pdf>.

3.Department of Health [online]. MRSA surveillance system – results. London: Department of Health, 7 March 2005. Available at: <http://www.dh.gov.uk/PublicationsAndStatistics/Publications/PublicationsStatistics/
PublicationsStatistics
Article/fs/en?CONTENT_ID=4085951&chk=HBt2QD>.

 

4.Letter from John Bacon, DH Director for Health and Social Care Delivery, and Christine Beasley, Chief Nursing Officer, Gateway ref. 4104, Healthcare Associated Infection and Hospital Cleanliness, 5 November 2004.

 

Outbreak of meningococcal disease in India – an update

 

 

An outbreak of meningococcal disease in Delhi, India, which began in March 2005 is continuing. As of 26 May 2005, 368 cases, including 37 deaths, have been reported. Forty-four per cent of cases are aged between 15 and 29 years, and this age group also accounts for 62% of deaths. Three times as many males are affected than females (1,2,3).

Contacts of the patients are being traced to provide them with chemoprophylaxis. Delhi hospitals are vaccinating people identified to be at risk with quadravalent meningococcal vaccine. Cerebrospinal fluid samples from patients are being tested, and 35 have so far been identified as Neisseria meningitidis serogroup A. The geographic distribution of cases reported in Delhi shows the highest numbers of cases in the zones of City, Shahdara North, Sadar Paharganj, Shahdara South, Civil Lines, and Central.

Meningococcal disease is endemic in India and sporadic cases have been known to occur in the Delhi area in previous years, but this is the first outbreak to be recorded in the area since 1985, when 6133 cases, including 799 deaths, were reported. Isolates from this outbreak were also confirmed as N. meningitidis serogroup A. Transmission of meningococcal disease is often associated with overcrowded conditions.

The World Health Organization (WHO) is providing technical support to the Delhi health authorities by assisting with epidemiological investigations, producing guidelines and tools and continuously monitoring the situation.

It is recommended that travellers to Delhi who will be visiting friends and family, or will be working or living in close contact with the local population, should consider vaccination with the quadrivalent meningococcal meningitis ACW135Y vaccine (4).

This news item has been adapted from Eurosurveillance Weekly (5).

 

References

 

1.World Health Organization Communicable Disease Surveillance and Response. Meningococcal disease in India – update 3. [online] [cited 8 June 2005]. Geneva: WHO, 30 May 2005. Available at <http://www.who.int/csr/don/2005_05_30a/en/index.html>.

 

2.World Health Organization Communicable Disease Surveillance and Response. Meningococcal disease in India. [online] [cited 8 June 2005]. Geneva: WHO, 9 May 2005 Available at <http://www.who.int/csr/don/2005_05_09/en/index.html>.

 

3.Health Protection Agency. Meningococcal Disease in India. Commun Dis Rep Wkly [serial online] 12 May 2005 [cited 8 June 2005]; 15(19): News. Available at <http://www.hpa.org.uk/cdr/archives/archive05/News/news1905.htm#meningo>.

 

4.United Kingdom National Travel Health Network and Centre. Clinical update [online]. Meningococcal disease in India. London: NaTHNaC, 10 May 2005. Available at <http://www.nathnac.org/pro/clinical_updates/MeningococcaldiseaseIndiaMay2005.htm>.

 

5.Eurosurveillance Weekly. Ongoing outbreak of meningococcal disease in India. Eurosurveillance Weekly [serial online] 2 June 2005 [cited 8 June 2005]; 10(22): Available at: <http://www.eurosurveillance.org/ew/2005/050602.asp#2>.